Scale and capabilities of the combined company position Elanco for the long term as a leader in the attractive, durable animal health industry. Combines Elanco’s longstanding focus on the veterinarian ...

In the animal health industry, one company in particular acts like a wolf on the prowl. Elanco Animal Health (NYSE: ELAN) is the world's second-largest animal health company and specializes in ...

Bayer’s eager to send its animal health unit to Elanco so it can focus its healthcare efforts on pharmaceuticals. But that $7.6 billion selloff, like many other recent life sciences deals, has hit an ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The head of Bayer Animal Health's North American operations ...

The deal was announced in August 2019 and was financed with $5.2 billion in cash and 72.9 million shares of Elanco. Management believes Bayer will help it strengthen its focus on the connections ...

July 22 (Reuters) - A former unit of German life-sciences giant Bayer (BAYGn.DE), opens new tab is squaring off in California federal court this week with a petcare startup that claims the company ...

Aug 2 (Reuters) - A former unit of German life-sciences giant Bayer convinced a federal jury in California on Thursday that it did not block a pet care startup from competing in the retail market for ...

Bayer AG (BAYN.XE) continues to pursue its plans to exit the animal-health business via a sale, the company said Thursday, following press reports of a potential deal with Elanco Animal Health Inc.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The U.S. Federal Trade Commission sent Elanco Animal Health ...

GREENFIELD, Ind.--(BUSINESS WIRE)-- Elanco Animal Health Incorporated (NYSE: ELAN) today announced it has closed the acquisition of Bayer Animal Health. The transaction, valued at $6.89 billion, ...

The merger with Bayer was transformational but came at a steep price. Elanco paid $5.2 billion in cash and issued 72.9 million in shares to Bayer. This makes it one of the most expensive deals in the ...